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uman adenovirus (HAdV) is a linear, non-
enveloped, double-stranded DNA virus that typi-
cally causes a mild respiratory, gastrointestinal, and
conjunctival illnesses in healthy persons.1 However,
HAdV may cause more severe infection in immunocom-
promised patients, especially those who have received
organ transplants. In kidney transplant recipients, uri-
nary tract infection is the most frequently reported
manifestation at 4.8%, with rare dissemination.2,3 In
a surveillance study, 6.5% of kidney transplant recip-
ients will have a positive polymerase chain reaction
(PCR) viremia within the first year, without significant
symptoms, that is self-limited.4 Disseminated HAdV,
defined as symptomatic disease of multiple organ sys-
tems and associated viremia, is infrequently reported
and is associated with transplant rejection, failure,
and mortality.5–10 A case of disseminated HAdV in a
kidney transplant recipient is reported, including a
review of management and outcomes in disseminated
disease with the goal to guide clinical decision making.
CASE REPORT
A 45-year-old man with a history of end-stage kidney
disease, secondary to chronic reflux nephropathy,
received a deceased donor kidney transplant. Induction
immunosuppression comprised antithymocyte glob-
ulin and methylprednisolone. Maintenance therapy
included tacrolimus, mycophenolate mofetil, and
prednisone. His clinical course was complicated by
delayed allograft function that required ongoing he-
modialysis for 4 weeks.
At his 6-week posttransplantation follow-up visit,
he reported a 2-day history of fever, fatigue, cough,
and hematuria. He was admitted to the hospital with
tachycardia, hypoxemia, and hypotension. He had
lymphopenia, thrombocytopenia, and a serum creati-
nine level of 1.73 mg/dl, compared to his baseline of
1.58 mg/dl. Urinalysis had sterile pyuria and hematu-
ria. Computed tomography of his chest showed an
opacity consistent with pneumonia. Vancomycin,
piperacillintazobactam, and levofloxacin were
empirically administered.
Over the next 3 days, he had nightly fevers. His
serum creatinine level increased to 2.4 mg/dl. Blood
cultures were negative. Studies for serum fungal–(1,3)-
B-D-glucan and Aspergillus galactomannan EIA, as
well as serum viral PCR cytomegalovirus and human
herpesvirus 6 infections, were negative. Urine BK viral
particles were not detected by PCR. A nasal swab was
positive for HAdV (PCR). Kidney ultrasound demon-
strated a 12.6-cm allograft without evidence of renal
artery stenosis and with high resistive indices of the
upper pole. The 24-hour urine protein was 0.5 g/d at
admission and increased to 3.3 g/d by hospital day 7.
A biopsy was performed on the kidney allograft.
Paraffin sections showed an edematous parenchyma
with a histiocyte-predominant nodular inflammatory
infiltrate resembling granulomatous tubulointerstitial
nephritis. In place of the epithelioid histiocytes char-
acteristic of granulomas, the predominant cell type in
the infiltrate was an atypical monocyte with an
eccentrically located, elongated, curved, and crinkled
nucleus. These cells infiltrated and distended the tu-
bules, many of which contained epithelial cells with
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nuclear viral inclusions as well as apoptic cells
(Figure 1). Inflammation with rupture of the tubule
appeared to give rise to nodules that, in areas, coalesced
into solid inflammatory infiltrate. Remnants of the
ruptured tubular basement membranes could be found
within the pseudogranulomas on periodic acid–Schiff
staining. Strong nuclear staining for adenovirus anti-
gen by cytopathic tubular epithelial cells confirmed
adenovirus infection (Arkana Laboratories, Little Rock,
AR). No histologic features of acute T-cell or antibody-
mediated rejection were found, and the immunofluo-
rescence stain for complement factor C4d was negative.
Testing for serum and urine HAdV by PCR returned at
102,801 copies/ml and > 2,000,000 copies/ml,
respectively.
Initial treatment consisted of reduction of the
patient’s immunosuppression by discontinuing myco-
phenolate mofetil and targeting a serum tacrolimus
trough level of 3 to 7 ng/ml. The prednisone dose was
increased from 5 mg to 10 mg daily. Because of the
ongoing severity of his allograft dysfunction and
associated respiratory illness, he was given i.v. Ig
dosed at 0.5 g/kg for 2 days. Symptomatic improve-
ment was reported by the second day after completion
of i.v. Ig. Serum creatinine and urine PCR HAdV DNA
levels declined steadily, with return to baseline and
resolution, respectively (Figure 2). The transplant team
was subsequently notified that the recipient of the
donor’s other kidney also developed disseminated
HAdV.
DISCUSSION
Kidney transplant recipients are at high risk over the
first 6 months after transplantation for infectious
complications, with bacterial cystitis as 1 of the most
common culprits.11 HAdV is well recognized in the
healthy population to be associated with self-limited
respiratory, gastroenteritis, and conjunctivitis illness.
However, in kidney transplant recipients, the spectrum
of HAdV activity ranges from asymptomatic viremia to
hemorrhagic cystitis to allograft loss and mortality.1,4-10
In the largest case series to date following 349 kidney
transplant recipients over a 3-year period, the inci-
dence of HAdV urinary infection and disseminated
disease was 4.8% and 3.1%, respectively. Onset of
disease was within the first 3 months in 75% of the
patients, and 97% were reported within 1 year.3,12 A
10-year review of 170 kidney transplant recipients
reported an incidence of 4.7% for hemorrhagic cystitis
with median time to onset of 1 year.2 In comparison,
recipients postallogenic stem cell transplantation
have a median time of diagnosis of adenovirus hemor-
rhagic cystitis and dissemination within the first few
weeks and month, respectively.13 Asymptomatic
HAdV viremia was reported as 6.5% from a surveil-
lance study, over a 1-year period, of 92 kidney trans-
plant recipients.4
HAdV in kidney transplant recipients may be
secondary to reactivation of latent disease, but infec-
tion also has been reported to be de novo from envi-
ronmental sources or from endogenous transmission
through a donor organ.1,5 The most frequent signs and
symptoms at presentation include dysuria, fever,
hematuria, sterile (bacterial) pyuriam and acute kidney
injury.2,3,12,14 Given the lack of specificity, a broad
differential for the etiology of nephritis must be
maintained.15 Common extrakidney manifestations
Figure 1. Kidney biopsy sample containing a virus-infected renal
tubule. Most of the renal tubular epithelial cells are lost or damaged
beyond recognition. Two of the residual epithelial cells contain
“smudged” intranuclear viral inclusions typical of adenovirus, with
nuclear enlargement and peripheral displacement of nuclear chro-
matin (black arrows). There is an associated intratubular and peri-
tubular infiltrate consisting predominantly of distinct histiocytes with
elongated, curved, and crinkled nuclei (open blue arrows). Periodic
acid–Schiff stain, original magnification 600.
Figure 2. Temporal trend of human adenovirus (HAdV) urine poly-
merase chain reaction (PCR), serum creatinine, and inception of
immunotherapy. Discontinuation of mycophenolate mofetil and
reduction of tacrolimus goal trough initiated at day 0, i.v. Ig 0.5 g/kg
received on days 8 and 9.
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among kidney transplant recipients with disseminated
disease include orchitis, lymphopenia, gastroenteritis,
and pneumonitis.3,16-18 Confirmatory diagnostic testing
is predominantly through HAdV PCR quantification
and tissue biopsy histopathological assessments. Viral
culture may be conducted in some cases.12 PCR is
sensitive to all known serotypes of HAdV, and has the
benefit of serial monitoring for response to treatment.
PCR testing for HAdV prognostication has been
reported in groups receiving hematopoietic stem cell
therapy and solid organ transplants.9,19,20
In the present case, this patient had a classically
defined presentation of disseminated HAdV. His kid-
ney biopsy findings of inclusion-bearing proximal
tubular cells and adjacent noncaseating granulomas in
the tubulointerstitium were consistent with HAdV
infection and confirmed by immunohistochemical
staining.21 Given the severity of his acute kidney
injury and progressive pneumonia, he was treated with
i.v. Ig based on reports for hematopoietic stem cell
transplant recipients.19,22–24 Cidofovir was not used
because of concerns about additional nephrotoxicity in
the setting of severe acute kidney injury in the trans-
planted kidney.
Clinically symptomatic patients with HAdV viremia
and 2 or more organ systems involved is considered
disseminated disease. Little has been published about
clinical management, and current recommendations for
treatment are lacking.10,25 Overall, 29 cases of dissem-
inated HAdV disease have been reported, including the
present case (Table 1). Adverse outcomes have been
reported in 6 cases (20%), including 4 deaths and 2
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2 Ardehali (35) 2001 Kidney 45/M, 6 yr Nephritis, pneumonitis,
gastritis, cardiac arrest
No PCR done, histological
confirmation
None Dead
3 Emovon (31) 2003 Kidney-Pancreas 46/F, 540 days HC, nephritis, septic shock No PCR, histopathology
confirmation
RBV þ i.v. Ig Alive, graft intact
4 Rosario (36) 2006 Kidney 58/M, 22 days Multiorgan failure, colitis PCR: þblood, þstool None; died prior to dx Dead
5 Alsaad (37) 2007 Kidney 19/M, 12 yr HC, pneumonia PCR: þurine/no serum testing CDV Alive, graft intact
6 Keswani (38) 2007 Kidney 5/M, 65 days HC, gastroenteritis PCR: þurine, þserum CDV Alive, graft intact
7 Saquib (39) 2009 Kidney 51/F, 6 yr Pneumonitis, diarrhea, HA, no
nephritis/HC
PCR: þurine, serum, stool,
BAL
CDV þ i.v. Ig Alive, graft intact
8 Kidney 62/M, 29 days PNA, colitis PCR: urine, þserum, þstool CDV þ i.v. Ig Alive, graft intact
9 Barraclough (26) 2009 Kidney 68/M, 14 days HC, nephritis, severe sepsis
with respiratory compromise
PCR: þurine, þserum, CSF CDV þ i.v. Ig Alive, graft intact
10 Gaspert (6) 2009 Kidney 64/M, 60 days HC, nephritis, pneumonitis PCR: þurine, þserum, þBAL None Alive, graft loss
11 Kozlowski (5) 2010 Kidney 44/M, 20 days HC, nephritis, pneumonitis PCR: þBAL GCV Alive, graft loss
12 Watcharananan (3) 2011 Kidney unkn HC, nephritis PCR: þserum None Alive, graft intact
13 Kidney unkn HC, orchitis, diarrhea PCR: þserum CDV þ i.v. Ig Alive, graft intact
14 Kidney unkn HC, pneumonitis, orchitis PCR: þserum CDV Dead
15 Kidney unkn HC, URI, orchitis PCR: þserum CDV Alive, graft intact
16 Kidney unkn HC, orchitis, graft rejection PCR: þserum CDV þ i.v. Ig Alive, graft intact
17 Kidney unkn HC, nephritis, enteritis PCR: þserum None Alive, graft intact
18 Kidney unkn HC, nephritis enteritis PCR: þserum None Alive, graft intact
19 Kidney unkn HC, leukopenia, enteritis PCR: þserum None Alive, graft intact
20 Varma (20) 2011 Kidney-Pancrease 57/M, 11 days Fever, neutropenia/leukopenia,
nephritis
PCR: þserum i.v. Ig Alive, graft intact
21 Sujeet (40) 2011 Kidney 65/F, 3 yr HC, nephritis, enteritis,
respiratory symptoms
PCR: þserum CDV Alive, graft intact
22 Parasuraman (18) 2013 Kidney 44/M, 22 days HC, nephritis, pneumonitis,
gastroenteritis
PCR: þurine, þserum CDV, i.v. Ig Alive, graft intact
23 Dawood (16) 2014 Kidney 70/F, 810 days HC, nephritis, gastroenteritis PCR: þurine, þserum, þstool CDV, i.v. Ig Alive, graft intact
24 Kidney 60/F, 28 days HC, nephritis, gastroenteritis PCR: þblood, þurine, þstool CDV, i.v. Ig Alive, graft intact
25 Lachiewicz (17) 2014 Kidney 20/F, 2 yr Nephritis, URI PCR: þurine, þserum CDV, i.v. Ig Alive, graft intact
26 Rady (41) 2014 Kidney 63/M, 42 days HC, nephritis, gastroenteritis PCR: þurine, serum not
performed
GCV, i.v. Ig Alive, graft intact
27 Park (42) 2015 Kidney 32/F, 180 days HC, nephritis, pneumonitis PCR: þurine, þserum RBV, i.v. Ig Alive, graft intact
28 Index case 2016 Kidney 45/M, 42 days HC, nephritis, pneumonitis PCR: þurine, þserum i.v. Ig Alive, graft intact
29 Veer (43) 2017 Kidney 75/F, 365 days HC, nephritis PCR: þurine, þserum i.v. Ig Alive, graft intact
BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; CDV, cidofovir; dx, diagnosis; F, female; GCV, ganciclovir; HA, headache; HC, hemorrhagic cystitis; M, male; PCR, polymerase
chain reaction; PNA, pneumonia; RBV, ribavirin; unkn, unknown; URI, upper respiratory infection; þ, positive; , negative.
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kidney allograft losses. In all, 21 case patients (72%)
received additional drug interventions along with
reduction of their immunosuppressive regimen. Cido-
fovir, used in 14 of 20 cases, was the most commonly
used antiviral agent, either alone or in combination
with i.v. Ig.
The first step in standard-of-care for HAdV in
transplant recipients is reduction of the immunosup-
pressive regimen. This intervention is often effective at
resolving cases of hemorrhagic cystitis and
nephritis.3,14 The usual indication for additional ther-
apies of antiviral or i.v. Ig is progressive disease despite
immunosuppression reduction.3,26 A PCR quantifica-
tion of 1 log reduction within 2 to 3 weeks is consid-
ered a therapeutic response.19 Antiviral therapies in
kidney transplant recipients include cidofovir, ganci-
clovir, ribavirin, and brincidofovir and i.v. Ig.27,28
Cidofovir, the most commonly used antiviral agent,
with activity against all serotypes of HAdV, is a
cytosine purine analogue that leads to chain termina-
tion.27,28 The primary adverse effect is hematological as
well as kidney toxicity.29 Cidofovir is not considered a
preferred therapy in kidney transplant recipients
owing to clearance by the kidney and risk of nephro-
toxicity. Brincidofovir (formally CMX101) is a new
lipid derivative of cidofovir. The lipid formulation al-
lows increased intracellular penetration that minimizes
proximal tubular accumulation, and as such, may
reduce the risk of nephrotoxicity.28 The AdVise Study
(NCT02087306), a currently completed phase III trial, is
predominantly a study of hematopoietic stem cell re-
cipients with small subset of solid organ transplant
recipients, evaluating brincidofovir for HAdV disease.
Results are expected to be reported soon.28,30 Ganci-
clovir, a 1-phoshorylated purine analog, has limited
effectiveness in HAdV, but there are case reports of its
use.2,4,28 Ribavirin, a nucleoside analogue of guanosine,
is also not generally recommended due to in vitro ac-
tivity against only subgroup C of HAdV. However, in
the posttransplantation population, subgroup C is a
common cause of disease.1,27,31 Intravenous Ig is pro-
posed to promote antiviral activity or to provide pas-
sive immunotherapy.32,33 Intravenous Ig has been used
in combination with cidofovir or as a single agent.
In conclusion, in kidney transplant recipients, HAdV
is an uncommonly recognized, but potentially serious,
infectious complication. This case reaffirms the clinical
context in which to consider such a viral source of
infection in kidney transplant recipients. We report
the successful management of disseminated HAdV with
i.v. Ig as a single agent along with reduction of immu-
nosuppressive therapy. Ongoing prospective studies of
HAdV surveillance and antiviral strategies are needed to
improve outcomes in this high-risk group.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We are grateful to our patient to disclose this case for
educational purposes and to the consultant physicians
who helped to guide this patient’s care.
REFERENCES
1. Lion T. Adenovirus infections in immunocompetent and
immunocompromised patients. Clin Microbiol Rev. 2014;27:
441–462.
2. Nanmoku K. Clinical characteristics and outcomes of adeno-
virus infection of the urinary tract after renal transplantation.
Transpl Infect Dis. 2016;18:234–239.
3. Watcharananan SP. Adenovirus disease after kidney trans-
plantation: course of infection and outcome in relation to
blood viral load and immune recovery. Am J Transplant.
2011;11:1308–1314.
4. Humar A, Kumar D, Mazzulli T, et al. A surveillance study of
adenovirus infection in adult solid organ transplant re-
cipients. Am J Transplant. 2005;5:2555–2559.
5. Kozlowski T, Nickeleit V, Andreoni K. Donor-transmitted
adenovirus infection causing kidney allograft nephritis and
graft loss. Transpl Infect Dis. 2011;13:168–173.
6. Gaspert A, Lüthi B, Mueller NJ, et al. Subacute allograft fail-
ure with dysuria and hematuria in a kidney transplant recip-
ient. Am J Kidney Dis. 2009;54:154–158.
7. Komiya T, Goto N, Takeda A, et al. A case of acute rejection
with adenovirus infection after ABO-incompatible kidney. Clin
Transplant. 2009;23(suppl 20):s27–s30.
8. Kolankiewicz LM, Pullman J, Raffeld M, et al. Adenovirus
nephritis and obstructive uropathy in a renal transplant
recipient: case report and literature review. Nephrol Dial
Transplant Plus. 2010;3:388–392.
9. Florescu MC, Miles CD, Florescu DF. What do we know about
adenovirus in renal transplantation? Nephrol Dial Transplant.
2013;28:2003–2010.
10. Echavarria M. Adenoviruses in immunocompromised hosts.
Clin Microbiol Rev. 2008;21:704–715.
11. Green M. Introduction: infections in solid organ trans-
plantation. Am J Transplant. 2013;13(suppl 4):3–8.
12. Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus
cystitis after renal transplantation. Transplant Proc. 2004;36:
3025–3027.
13. Taniguchi K, Yoshihara S, Tamaki H, et al. Incidence and
treatment strategy for disseminated adenovirus disease after
haploidentical stem cell transplantation. Ann Hematol.
2012;91:1305–1312.
14. Hensley JL, Sifri CD, Cathro HP, et al. Adenoviral graft-
nephritis: case report and review of the literature. Trans-
plant Int. 2009;22:672–677.
15. Raghavan R, Eknoyan G. Acute interstitial nephritis—a reap-
praisal and update. Clin Nephrol. 2014;82:149–162.
16. Dawood US, Nelson A, Wu D, et al. Disseminated adenovirus
infection in kidney transplant recipient. Nephrology. 2014;19:
10–13.
NEPHROLOGY ROUNDS T Hatlen et al.: Disseminated Adenovirus After Kidney Transplantation
22 Kidney International Reports (2018) 3, 19–23
17. Lachiewicz AM, Cianciolo R, Miller MB, Derebail VK. Adeno-
virus causing fever, upper respiratory infection, and allograft
nephritis complicated by persistent asymptomatic viremia.
Transpl Infect Dis. 2014;16:648–652.
18. Parasuraman R, Zhang PL, Samarapungavan D, et al. Severe
necrotizing adenovirus tubulointerstitial nephritis in a kidney
transplant recipient. Case Rep Transplant. 2013; article ID
969186, http://dx.doi.org/10.1155/2013/969186.
19. Leruez-Ville M. Real-time blood plasma polymerase chain
reaction for management of disseminated adenovirus infec-
tion. Clin Infect Dis. 2004;38:45–52.
20. Varma MC, Kushner YB, Ko DS, et al. Early onset adenovirus
infection after simultaneous kidney-pancreas transplant. Am
J Transplant. 2011;11:623–627.
21. Asim M, Chong-Lopez A, Nickeleit V. Adenovirus infection of
a renal allograft. Am J Kidney Dis. 2003;41:696–701.
22. Echavarria M, Forman M, van Tol MJD, et al. Prediction of
severe disseminated adenovirus infection by serum PCR.
Lancet. 2001;358:384–385.
23. Lankester AC, van Tol MJ, Claas EC, et al. Quantification of
adenovirus DNA in plasma for management of infection in
stem cell graft recipients. Clin Infect Dis. 2002;34:864–867.
24. Schilham MW, Claas EC, van Zaane W, et al. High levels of
adenovirus DNA in serum correlate with fatal outcome of
adenovirus infection in children after allogeneic stem-cell
transplantation. Clin Infect Dis. 2002;35:526–532.
25. Ison MG, Green M. AST Infectious Diseases Community of
Practice: adenovirus in solid organ transplant recipients. Am
J Transplant. 2009;9:S161–S165.
26. Barraclough K, Oliver K, Playford EG, et al. Life-threatening
adenovirus infection in a kidney transplant recipient. Nephrol
Dial Transplant Plus. 2009;2:250–253.
27. Ison MG. Adenovirus infections in transplant recipients. Clin
Infect Dis. 2006;43:331–339.
28. Wold WS, Toth K. New drug on the horizon for treating
adenovirus. Expert Opinion Pharmacother. 2015;16:
2095–2099.
29. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for
adenovirus infections after allogeneic hematopoietic stem
cell transplantation: a survey by the Infectious Diseases
Working Party of the European Group for Blood and
Marrow Transplantation. Bone Marrow Transplant. 2003;31:
481–486.
30. Clinicaltrials.gov. Phase III, open-labeled, multicenter study of
the safety and efficacy of Brincidofovir (CMX001) in the
treatment of early versus late adenovirus infection (CMX001
Adv). Available at: https://clinicaltrials.gov/ct2/show/study/
NCT02087306?term¼brincidofovir&rank¼1. Accessed May
20, 2017.
31. Emovon OE, Lin A, Howell DN, et al. Refractory adenovirus
infection after simultaneous kidney-pancreas transplantation:
successful treatment with intravenous ribavirin and pooled
human intravenous immunoglobulin. Nephrol Dial Trans-
plant. 2003;18:2436–2438.
32. Sener A, House AA, Jevnikar AM, et al. Intravenous immu-
noglobulin as a treatment for BK virus associated nephrop-
athy: one-year follow-up of renal allograft recipients.
Transplantation. 2006;81:117–120.
33. Broeders EN, Wissing KM, Hazzan M, et al. Evolution of
immunoglobulin and mannose binding protein levels after
renal transplantation: association with infectious complica-
tions. Transpl Int. 2008;21:57–64.
34. Myerowitz RL, Stalder H, Oxman MN, et al. Fatal dissemi-
nated adenovirus infection in a renal transplant recipient. Am
J Med. 1975;59:591–598.
35. Ardehali H, Volmar K, Roberts C, et al. Fatal disseminated
adenoviral infection in a renal transplant patient. Trans-
plantation. 2001;71:998–999.
36. Rosario RF, Kimbrough RC, Van Buren DH, Laski ME. Fatal
adenovirus serotype-5 in a deceased-donor renal transplant
recipient. Transpl Infect Dis. 2006;8:54–57.
37. Alsaad KO, Tobar A, Belanger E, et al. Late-onset acute hae-
morrhagic necrotizing granulomatous adenovirus tubu-
lointerstitial nephritis in a renal allograft. Nephrol Dial
Transplant. 2007;22:1257–1260.
38. Keswani M, Moudgil A. Adenovirus-associated hemorrhagic
cystitis in a pediatric renal transplant recipient. Pediatr
Transplant. 2007;11:568–571.
39. Saquib R, Melton LB, Chandrakantan A, et al. Disseminated
adenovirus infection in renal transplant recipients: the role of
cidofovir and intravenous immunoglobulin. Transpl Infect
Dis. 2010;12:77–83.
40. Sujeet K, Vasudev B, Desai P, et al. Acute kidney injury
requiring dialysis secondary to adenovirus nephritis in renal
transplant recipient. Transpl Infect Dis. 2011;13:174–177.
41. Rady K, Walters G, Brown M, Talaulikar G. Allograft adeno-
virus nephritis. Clin Kidney J. 2014;7:289–292.
42. Park UJ, Hyun SK, Kim HT, et al. Successful treatment of
disseminated adenovirus infection with ribavirin and intra-
venous immunoglobulin in an adult renal transplant recip-
ient: a case report. Transplant Proc. 2015;47:791–793.
43. Veer M, Abdulmassih R, Como J, et al. Adenoviral nephritis in
a renal transplant recipient: case report and literature review.
Transpl Infect Dis. 2017:e12716.
T Hatlen et al.: Disseminated Adenovirus After Kidney Transplantation NEPHROLOGY ROUNDS
Kidney International Reports (2018) 3, 19–23 23
